Imperative Care Valuation, Funding & Investors

Imperative Care is valued at $1.7B as of July 2024.

Last Imperative Care valuation

$1.7B

Series E · Jul 2024

Last Imperative Care funding round

$100M

Undisclosed stage · Mar 2026

Cumulative funding Imperative Care raised

$619M

across 6 funding rounds

Key investors in Imperative Care

  • Bain Capital
  • Ally Bridge Group
  • Rock Springs Capital
  • D1 Capital Partners
  • Catalio Capital Management
  • Ascension Ventures

Imperative Care Overview

About Imperative Care

Imperative Care is a medical device company advancing stroke treatment technologies. Its portfolio includes aspiration systems and access catheters designed for rapid thrombectomy and improved patient outcomes. Alameda-headquartered, the firm addresses ischemic stroke intervention needs in hospitals worldwide.


Founded

2015

HQ

United StatesSan Jose, CA

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$1.7B (Jul 2024)

Imperative Care Valuation

Imperative Care is currently valued at $1.7B, based on its Series E in July 2024.

The $150M round was led by Ally Bridge Group, with participation from Montreux Equity Partners, Innovatus Capital Partners, HealthCor Family Office, Catalio Capital Management, Rock Springs Capital and 5 other investors.

Imperative Care's valuation has grown 1.2x from $1.4B at its Series D in July 2021 to $1.7B in July 2024, across 2 priced rounds.

Imperative Care valuation by funding round

Imperative Care valuation by funding round
DateStageValuation
Jul 2024Series E$1.7B
Jul 2021Series D$1.4B

Imperative Care Funding History

Imperative Care has raised a total of $619M across 6 funding rounds.

Imperative Care's first fundraising round was a $3M seed round in April 2017. The most recent completed round was a $100M undisclosed-stage round in March 2026.

Imperative Care funding rounds

Imperative Care funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Mar 2026Undisclosed stageElevage Medical Technologies (lead); Perceptive Advisors (lead); Longaeva Partners; Catalio Capital Management; Brown Advisory US Smaller; Bain Capital; Ally Bridge Group$100M--
Jul 2024Series EAlly Bridge Group (lead); Montreux Equity Partners; Innovatus Capital Partners; HealthCor Family Office; Catalio Capital Management; Rock Springs Capital; D1 Capital Partners; Intai Technology; Bain Capital; Pura Vida Investments; AMED Ventures$150M$1.7BImperative Care is a medical technology company developing devices and digital health solutions for stroke and vascular thrombectomy, including the Zoom aspiration system for clot removal and the Kandu Health platform for remote patient monitoring post-stroke. The company announced an oversubscribed Series E financing round on July 25, 2024, led by Ally Bridge Group, with participation from existing investors AMED Ventures, Bain Capital Life Sciences, D1 Capital Partners, Innovatus Capital Partners, Pura Vida Investments, and Rock Springs Capital, plus new investors Catalio Capital Management, HealthCor Family Office, Intai Technology, and Montreux Equity Partners. Sources describe the round as potentially up to $150 million across multiple tranches (E-1 $75M, E-2 $50M, E-3 $25M) or $72.63M in aggregate, at a post-money valuation of $1.66 billion and $6.87 price per share. Proceeds are intended to fuel hypergrowth, support commercialization of stroke and vascular thrombectomy portfolios, invest in next-generation products like the Telos robotic platform, and generate clinical evidence on patient outcomes. The financing reflects strong investor confidence in Imperative Care's momentum in addressing treatment gaps for thromboembolic diseases. Shacey Petrovic was appointed vice chair of the board alongside the announcement. Previously, Imperative Care raised $260 million in a Series D round on July 15, 2021, at a $1.35 billion post-money valuation with overlapping investors including Ally Bridge Group. A separate $100 million convertible note financing was closed more recently, co-led by Elevage Medical Technologies and Perceptive Advisors with Catalio Capital Management, supported by Ally Bridge Group and Bain Capital Life Sciences, to further commercialization and R&D.
Jul 2021Series DD1 Capital Partners (lead); Innovatus Capital Partners; Delos Capital; HealthCor Partners; Rock Springs Capital; Bain Capital; Ascension Ventures; AMED Ventures; Ally Bridge Group$260M$1.4BImperative Care, Inc. is a medical technology company focused on advancing treatments for thromboembolic diseases, particularly in stroke care and peripheral vascular disease. The company develops innovative devices for stroke intervention and thrombectomy, with two FDA-cleared devices at the time of the Series D round. In July 2021, Imperative Care closed a $260 million Series D financing round led by D1 Capital Partners, with participation from new investors HealthCor Investments and Innovatus Capital Partners, as well as existing investors including Ally Bridge Group, AMED Ventures (Amed Ventures), Ascension Ventures, Bain Capital Life Sciences, Delos Capital, and Rock Springs Capital. By this round, Imperative Care had raised over $300 million since its 2015 founding. Proceeds were earmarked to advance marketing and development of Imperative Care's stroke care technologies, form strategic wholly-owned development subsidiaries, and support the integration of Truvic Medical, a peripheral thrombectomy firm acquired in a stock-for-stock deal using round proceeds. Truvic's technologies target peripheral vascular disease treatment, expanding Imperative Care's portfolio beyond stroke into synergistic areas. Post-Series D, Imperative Care continued growth with later rounds including a $100 million convertible note and Series E financings in 2024 totaling around $150 million at a $1.66 billion valuation, reflecting ongoing investor support from many of the same backers plus new ones like Catalio Capital Management. The company positioned itself to build a portfolio of stroke and vascular technologies, including next-generation products like the Telos robotic platform.
Dec 2019Series CAlly Bridge Group (lead); Bain Capital (lead); Delos Capital; Incept LLC; Rock Springs Capital; Ascension Ventures$85M-Imperative Care, Inc. is a medical technology company developing neurovascular devices for treating ischemic and hemorrhagic strokes, including the ZOOM Aspiration System and Large Distal Platform access catheters, both FDA-cleared by 2019. The company completed the initial closing of an $85 million Series C financing around October/December 2019, co-led by Ally Bridge Group and Bain Capital Life Sciences, with participation from existing investors Ascension Ventures, Delos Capital, Rock Springs Capital, 3H Health Investment, and Incept LLC. Frank Yu of Ally Bridge and Andrew Hack, M.D., Ph.D., of Bain Capital joined the board. Proceeds supported the commercial launch of Imperative Care's stroke treatment portfolio, emphasizing clinical evidence and pipeline development. The financing occurred at a key growth stage following FDA clearances, positioning the company to expand market access for its innovative aspiration and access technologies. Subsequent rounds included a Series D of $260 million in July 2021 and later Series E (up to $150 million, initial close led by Ally Bridge Group) and $100 million convertible note financings.
Jul 2017Undisclosed stage-$21M-Imperative Care is a medical technology company developing neurovascular devices for treating ischemic and hemorrhagic strokes, including the ZOOM Aspiration System and Large Distal Platform access catheters. The company received FDA 510(k) clearance for these products around the time of its earlier funding rounds. Subsequent rounds included a Series C financing with an initial closing of $85 million announced around November 2019, co-led by Ally Bridge Group and Bain Capital Life Sciences, with participation from existing investors like Ascension Ventures, Delos Capital, Rock Springs Capital, 3H Health Investment, and Incept LLC. This supported the commercial launch of its stroke treatment portfolio. Later financings encompassed a Series D of $260 million in July 2021 at a post-money valuation of $1.35 billion, and multiple Series E tranches in 2024 totaling around $150 million at $1.66 billion post-money valuation, involving investors such as Ally Bridge Group, Bain Capital Life Sciences, D1 Capital Partners, and others. A $100 million convertible note financing was also announced, co-led by Elevage Medical Technologies and Perceptive Advisors, with participation from Catalio Capital Management, Longaeva Partners, Brown Advisory, Ally Bridge Group, and Bain Capital Life Sciences, to fund commercialization of stroke and vascular thrombectomy products, next-generation development like the Telos robotic platform, and clinical evidence generation.
Apr 2017Seed-$3M-Imperative Care, a medical technology company spun off from Incept in 2015, develops devices for stroke treatment, including access catheters for brain blood vessels and clot removal systems for ischemic strokes. Regulatory filings indicate it received $3 million in funding in April 2017 from undisclosed investors, followed by $21 million three months later. These early rounds contributed to the company's growth ahead of larger financings like the $85 million Series C in February 2020 and $260 million Series D in July 2021.

Who has invested in Imperative Care?

19 investors have backed Imperative Care across its funding rounds, including Bain Capital, Ally Bridge Group, Rock Springs Capital, D1 Capital Partners, Catalio Capital Management and Ascension Ventures.

Lead investors include Elevage Medical Technologies, Perceptive Advisors, Ally Bridge Group, D1 Capital Partners and Bain Capital.


Imperative Care Investors

Investors in Imperative Care by funding rounds participated
InvestorHQRoundsRoleFirst check
Bain CapitalUnited StatesBoston, MA4LeadDec 2019
Ally Bridge GroupHong KongHong Kong4LeadDec 2019
Rock Springs CapitalUnited StatesBaltimore, MD3ParticipantDec 2019
Innovatus Capital PartnersUnited StatesNew York City, NY2ParticipantJul 2021
Delos CapitalUnited StatesNew York City, NY2ParticipantDec 2019
Catalio Capital ManagementUnited StatesNew York City, NY2ParticipantJul 2024
D1 Capital PartnersUnited StatesNew York City, NY2LeadJul 2021
Ascension VenturesUnited StatesClarkton, NC2ParticipantDec 2019
AMED VenturesUnited StatesSan Francisco, CA2ParticipantJul 2021
Montreux Equity PartnersUnited StatesSan Francisco, CA1ParticipantJul 2024
HealthCor Family OfficeUnited StatesNew York City, NY1ParticipantJul 2024
Longaeva PartnersUnited StatesNew York City, NY1ParticipantMar 2026
Incept LLCUnited StatesSan Francisco, CA1ParticipantDec 2019

This data is available for Pro users. Sign up to see all 19 Imperative Care investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Imperative Care Competitors

Imperative Care competitors include listed companies like Immunocore Holdings, 4DMedical, Alphatec Holdings and Jafron Biomedical, and private ones like Rakuten Medical and MicroPort NeuroTech.

Public and private companies comparable to Imperative Care
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Immunocore HoldingsUnited StatesUnited StatesPublicly listed$400M($20M)$1.7B2.8x
4DMedicalAustraliaAustraliaPublicly listed$4M($18M)$1.6B193.3x
Rakuten MedicalUnited StatesSan Diego, CAPrivate--$1.7B-
Alphatec HoldingsUnited StatesUnited StatesPublicly listed$764M($15M)$1.6B2.5x
MicroPort NeuroTechChinaShanghaiPrivate$56M-$1.8B31.3x
Jafron BiomedicalChinaChinaPublicly listed$300M$123M$1.8B5.2x

Imperative Care Public Comps

Imperative Care is still privately-owned, but its public comps include Immunocore Holdings, Nihon Kohden, Edge Medical, 4DMedical, Nakanishi, Alphatec Holdings, SKAN Group, Cofoe Medical, Shanghai MicroPort and Embla Medical.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Immunocore Holdings$400M($20M)3.1x2.8x(60.8x)(57.8x)
Nihon Kohden$1.5B$166M1.0x1.0x8.8x8.9x
Edge Medical$68M($10M)22.9x14.3x(153.6x)241.6x
4DMedical$4M($18M)349.4x193.3x(81.1x)(25.2x)
Nakanishi$522M$53M2.8x2.5x27.5x9.7x
Alphatec Holdings$764M($15M)2.7x2.5x(140.5x)16.6x
SKAN Group$406M$43M4.5x3.9x42.0x28.5x
Cofoe Medical$505M$89M2.9x2.4x16.2x15.0x

This data is available for Pro users. Sign up to see all Imperative Care competitors and their valuation data.

Start Free Trial

Common questions about Imperative Care

When was Imperative Care founded?Imperative Care was founded in 2015.
Where is Imperative Care headquartered?Imperative Care is headquartered in San Jose, CA, United States.
Is Imperative Care publicly listed?No, Imperative Care is a private, VC-backed company.
What is Imperative Care's valuation?Imperative Care was last valued at $1.7B in its Series E in July 2024.
How much funding has Imperative Care raised?Imperative Care has raised $619M across 6 funding rounds.
What was Imperative Care's last funding round?Imperative Care's last funding round was a $100M undisclosed-stage round in March 2026, led by Elevage Medical Technologies and Perceptive Advisors.
Who are Imperative Care's investors?Imperative Care's investors include Bain Capital, Ally Bridge Group, Rock Springs Capital, Innovatus Capital Partners, Delos Capital, Catalio Capital Management, D1 Capital Partners, Ascension Ventures, AMED Ventures, Montreux Equity Partners and 9 others.
Which companies are comparable to Imperative Care?Companies comparable to Imperative Care include Immunocore Holdings, 4DMedical, Rakuten Medical, Alphatec Holdings, MicroPort NeuroTech and Jafron Biomedical.

See companies similar to Imperative Care

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial